Molecular markers in colon cancer are needed for a more accurate classification and personalized treatment. We determined the effects on clinical outcome of the BRAF mutation, microsatellite instability (MSI) and KRAS mutations in stage II and III colon carcinoma.
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Introduction
Colon carcinoma is classified according to clinical and histopathological criteria.
Prognosis and therapy relate to this classification. According to the Dutch treatment guidelines previous to 2006, stage II patients were solely treated with surgery. Stage III patients would receive adjuvant chemotherapy after surgery. Around 20% of stage II patients will develop a relapse in the first five years after surgery. Probably, this group of patients would benefit from adjuvant chemotherapy. On the other hand, 60% of stage III patients are cured after surgery and do not benefit from the adjuvant treatment 1 2 .
Hence, other criteria for adjuvant therapy are needed. Molecular markers might prove to be better than clinical and histopathological criteria for therapy selection.
Microsatellite instability (MSI) and KRAS mutations have been widely studied in colorectal cancer. Around 20% of the sporadic colon cancers show MSI due to defects in the mismatch repair system (MMR). MSI is associated with a better prognosis [3] [4] [5] [6] .
Approximately 35% of colon cancers carry a mutation in codons 12 or 13 of the KRAS gene leading to the constitutive activation of its downstream pathway and to uncontrolled cell division [7] [8] [9] . BRAF is recently being studied in relation to prognosis [10] [11] [12] [13] .
BRAF is a downstream effector molecule of KRAS. 90% of the BRAF mutations consist in a valine to glutamate transition at position 600 of the protein, the so called V600E mutation, which causes the constitutive activation of the protein. This mutation is
found in approximately 20% of the colonic tumors.
Mutations in BRAF and in KRAS are mutually exclusive. Tumors harboring the V600E BRAF mutation have other clinical and histopathological features than KRAS mutated tumors 14 .
The value of KRAS mutations in stage II and III is unknown. BRAF has been studied only in heterogeneous colon carcinoma patients cohorts including all disease stages [10] [11] [12] and recently in a group of stage IV colorectal cancer 13 
Molecular characterization
BRAF mutation analysis
The V600E mutation on the BRAF gene was detected by means of real time PCR using like described elsewhere 15 . A PCR product of 136 bp was obtained. The assay showed to have a detection limit of at least 10% tumor cells in a given specimen. All PCR reactions were performed on the Light Cycler v2.0 (Roche, Almere, the Netherlands) using Roche chemistry in a total volume of 20 microliters.
Microsatellite instability
Microsatellite instability was detected using only one marker of the Bethesda panel, i.e.
the mononucleotide repeat BAT26. This marker was chosen because in the Caucasian race, it detects 99% of the MSI high patients and normal DNA is not necessary 16, 17 .
PCR was performed using the following primers, forward VIC-5´TGA CTA CTT TTG ACT TCA GCC 3´ and reverse 5´ACC CAT TCA ACA TTT TTA ACC C 3´. The expected product length is 116 bp. Subsequently, PCR products were diluted depending on their intensity and denatured using formamide and incubated at 95°C for 3 minutes. Products size were analyzed using the ABI3130 (Applied Biosystems, Nieuwerkerk aan de Ijssel, the Netherlands) and GeneMapper 4.0 software package.
KRAS mutation analysis
Mutations in codons 12 and 13 of the KRAS gene were detected by DNA sequencing.
Briefly, PCR amplification of the cited codons was performed using the following primers; forward 5´AGG CCT GCT GAA AAT GAC TG 3´and reverse 5´TCA AAG AAT GGT CCT GCA CC 3´ as previously described by van Zandwijk et al 18 . The expected product length was 172 bp. After purification of the PCR product, the sequence reaction was performed using the same primers independently and the Big Dye reagents (Applied Biosystems, Nieuwerkerk aan de Ijssel, the Netherlands). Products were separated on the ABI3130 (Applied Biosystems, Nieuwerkerk aan de Ijssel, the Netherlands). The sequences were evaluated with the Sequencing Analysis 5.3.1 software. 
Statistical Analysis
KRAS, BRAF and MSI status
Survival analysis
In a univariate analysis, in both groups separately the BRAF V600E mutation was In the stage III group, KRAS mutations seemed to confer a significantly worse DFS than KRAS wild type (p=0.03) (Figure 3 ). This effect was not present in the stage II group.
Multivariate analysis
Since results did not significantly differ between both populations, data of both 16 (20) 6 (55) 62 (80) 5 (45) 0.024 BRAF wt mut 73 (78) 21 (22) 41 (57) 21 (100) 31 (43) 0 (0) <0.001
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8 (11) 15 (71) 65 (89) 22 (96) 40 (57) 1 (4) 30 (43) 0.001 45 (74) 44 (65) 28 (61) 13 (54) 16 (26) 24 (35) 18 (39) 11 (46) 0.3
12 (18) 8 (11) 7 (15) 3 (12) 54 (82) 63 (89) 40 (85) 22 (88) 0.7 (14) 179 (86) 14 (50) 149 (86) 14 (50) 24 (14)
T-status
<0.001
25 (93) 103 (61) 2 (7) 67 ( 
Discussion
The molecular signature of a tumor will most likely influence patient survival. In stage II and III colon cancer the use of molecular markers might be particularly important in order to offer the most adequate therapy to each patient and avoid unnecessary chemotherapeutic treatment. In this study, we assessed the effect of the V600E BRAF mutation, KRAS mutations and MSI on patient outcome, in two well defined colon cancer populations of stage II and III patients.
In our population, the V600E BRAF mutation is an independent prognostic factor. 13 .
However, the patients included in that study did all receive palliative chemotherapy and therefore no conclusion could be drawn about either the prognostic or predictive value of the BRAF mutation. From our data, we can conclude that the BRAF mutation is an independent prognostic factor in all patients with stage II and III colon carcinoma.
It could be argued that our selection of patients based on the therapy according to the guidelines could bias the results. However, identical results were obtained in a larger group including stage III patients who did not receive adjuvant chemotherapy (data not shown).
Moreover, concordant with the literature 10, 12 , the V600E BRAF mutation identifies a small group of patients with microsatellite stable tumors who had a poor survival. However, the interaction between MSI, BRAF and disease outcome remains subject of study since in the multivariate analysis, MSI seemed to play a marginal role depending on therapy in patients' survival. . The use of only one marker could have diminished the sensitivity of our analysis but not the specificity 16, 17 . The higher frequency of MSI tumors in stage II is probably due to the significant association of MSI and right sided tumors and the higher proportion of these tumors among stage II patients which in turn can be explained by the shift in tumor location that occurs as patient age increases 22 .
Due to the retrospective character of this study, we were not able to test patients Eighty four percent of our stage II patients would be nowadays considered as high risk patients. The majority due to the insufficient number of lymph nodes examined.
Therefore, we can conclude that the negative effects of the V600E BRAF mutation on survival are applicable to this group of patients and that this mutation can be considered as a prognostic marker.
In conclusion, BRAF is an independent prognostic factor in stage II and III colon cancer. These results are promising for the treatment of colon cancer patients since determination of the V600E BRAF mutation can discriminate between patients who have a shorter OS, DFS and CSS. The exact effect of MSI and of KRAS on survival should be further elucidated. In contrast, this BRAF mutation might become an important molecular marker in the future for drug development and in the decision making for patient tailored adjuvant therapy.
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